Literature DB >> 27497376

Pediatric malignant salivary gland tumors: 60 year follow up.

Cara C Cockerill1, Brian C Gross2, Stephanie Contag3, Sarah Rein4, Eric J Moore5, Kerry D Olsen6, Laura J Orvidas7.   

Abstract

OBJECTIVE: To evaluate the presentation, treatments and outcomes in pediatric patients with salivary gland malignancies. STUDY
DESIGN: Retrospective chart review (1950-2012), Prospective phone interview.
METHODS: Patients ≤18 years old with a salivary gland malignancy treated at our institution were identified. Patients were also contacted by phone for a follow up survey.
RESULTS: Fifty-six patients were identified. Tumor origin was 88% parotid (n = 49), 5% (n = 3) submandibular and 7% (n = 4) minor salivary glands. Time from onset of symptoms to diagnosis was over one year (mean = 14.4 years). Fifteen out of 52 patients with major gland malignancy had a locoregional recurrence and local recurrences were almost all after initial enucleation. Two of these patients died of disease (overall disease specific survival = 96%). Three out of 4 patients with minor gland malignancy had a local recurrence and two patients with high grade pathology developed metastases and died of their disease (overall survival = 50%). On long term follow up survey in 13 patients (25%), 100% reported normal facial movement and 54% described symptoms of Frey's syndrome, which is higher than other reported series in children. Recurrence was noted up to 45 years after initial treatment.
CONCLUSIONS: The majority of malignant pediatric salivary gland tumors are low grade and have excellent survival, especially if found at an early stage. Minor salivary gland malignancies, particularly high grade, have a worse prognosis. Long term mild Frey's syndrome can be expected in approximately half of patients. We advocate a need for long term follow up and increased awareness among providers to diagnose these patients earlier.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Outcome; Pediatric; Salivary gland; Tumor

Mesh:

Year:  2016        PMID: 27497376     DOI: 10.1016/j.ijporl.2016.05.021

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  4 in total

1.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

2.  Oncologic outcome of parotid mucoepidermoid carcinoma in pediatric patients.

Authors:  Qigen Fang; Fei Liu; Dongjie Seng
Journal:  Cancer Manag Res       Date:  2019-01-29       Impact factor: 3.989

3.  Salivary gland cancer in Southern Brazil: a prognostic study of 107 cases.

Authors:  V-G Zanella; V-P Wagner; T-R Schmidt; S Thieme; C Correa; F-P Fonseca; P Rigon; M-B Barra; R-G Kroef; P-A Vargas; M-D Martins
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2021-05-01

4.  Are demographics associated with mucoepidermoid or acinic cell carcinoma parotid malignancies in children?

Authors:  Tyler A Janz; Eric J Lentsch; Shaun A Nguyen; Clarice S Clemmens
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.